H
Hans von der Maase
Researcher at Aarhus University Hospital
Publications - 47
Citations - 4062
Hans von der Maase is an academic researcher from Aarhus University Hospital. The author has contributed to research in topics: Bladder cancer & Survival rate. The author has an hindex of 22, co-authored 47 publications receiving 3734 citations. Previous affiliations of Hans von der Maase include Aarhus University.
Papers
More filters
Journal ArticleDOI
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
Hans von der Maase,Lisa Sengeløv,J. T. Roberts,Sergio Ricci,Luigi Dogliotti,Tim Oliver,Malcolm J. Moore,Annamaria Zimmermann,M. Arning +8 more
TL;DR: Compared with a large randomized phase III study of GC versus MVAC, long-term survival in patients with locally advanced or metastatic transitional cell carcinoma of the urothelium treated with gemcitabine/cisplatin or methotrexate/vinblastine/doxorubicin/c isplatin was similar in both arms.
Journal ArticleDOI
Phase II study on stereotactic body radiotherapy of colorectal metastases.
Morten Høyer,Henrik Roed,Anders Traberg Hansen,Lars Ohlhuis,Jørgen B. B. Petersen,Hanne Marie Nellemann,Anne Kiil Berthelsen,Cai Grau,Svend Aage Engelholm,Hans von der Maase +9 more
TL;DR: Testing the effect of stereotactic body radiotherapy (SBRT) in patients with inoperable CRC-metastases resulted in high probability of local control and promising survival rate.
Journal ArticleDOI
Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma
Morten Høyer,Henrik Roed,Lisa Sengeløv,Anders Traberg,Lars Ohlhuis,Jorgen Pedersen,Hanne Marie Nellemann,Anne Kiil Berthelsen,Frey Eberholst,Svend Aage Engelholm,Hans von der Maase +10 more
TL;DR: SRT was associated with poor outcome, unacceptable toxicity and questionable palliative effect and cannot be recommended for patients with advanced pancreatic carcinoma.
Journal ArticleDOI
Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma
Frede Donskov,Hans von der Maase +1 more
TL;DR: Three independent immunologic parameters had significant discriminatory power as supplemental risk factors in prognostic models based on the clinical risk factors, identifying subgroups within the favorable clinical group with estimated 5-year survival rates of 60%, 25%, and 0%, respectively.
Journal ArticleDOI
Surveillance following orchidectomy for stage I seminoma of the testis
Hans von der Maase,Lena Specht,G K Jacobsen,Anders Lund Jakobsen,Madsen El,M. Pedersen,Mikael Rørth,Henrik Schultz +7 more
TL;DR: Patients with tumours > or = 6 cm will now be given prophylactic radiation treatment, whereas the nationwide Danish study of surveillance only for testicular seminoma stage I will continue to use surveillance only after orchidectomy for patients with tumour < 6 cm.